Literature DB >> 17852582

Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale.

Erin E Morgan1, Steven Paul Woods, J Cobb Scott, Meredith Childers, Jennifer Marquie Beck, Ronald J Ellis, Igor Grant, Robert K Heaton.   

Abstract

The aim of the current study was to develop and validate demographically adjusted normative standards for the HIV Dementia Scale (HDS). Given the association between demographic variables and the HDS summary score, demographically adjusted normative standards may enhance the classification accuracy of the HDS. Demographically adjusted normative standards were derived from a sample of 182 seronegative healthy participants and were subsequently applied to a sample of 135 HIV-1 seropositive individuals with multidisciplinary case conference diagnoses of HIV-1-associated neurocognitive disorders (e.g., HIV-1-associated dementia and minor-cognitive/motor disorder) in proportions consistent with published epidemiologic reports. In the normative sample, age and education (and their interaction) emerged as the only demographic factors significantly associated with the HDS. In comparison to the traditional HDS cut score (raw score total <or=10), use of the demographically adjusted normative standards significantly improved the sensitivity (from 17.2% to 70.7%, respectively) and overall classification accuracy (increasing the odds ratio from 3 to approximately 6) of the HDS for identifying participants with HIV-1-associated neurocognitive disorders. The application of demographically adjusted normative standards on the HDS improves the clinical applicability and accuracy of this cognitive screening measure in the detection of HIV-1-associated neurocognitive disorders.

Entities:  

Mesh:

Year:  2007        PMID: 17852582      PMCID: PMC3659773          DOI: 10.1080/13803390701233865

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  13 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Bedside assessment of executive cognitive impairment: the executive interview.

Authors:  D R Royall; R K Mahurin; K F Gray
Journal:  J Am Geriatr Soc       Date:  1992-12       Impact factor: 5.562

Review 3.  Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.

Authors: 
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

4.  Initial validation of a screening battery for the detection of HIV-associated cognitive impairment.

Authors:  Catherine L Carey; Steven Paul Woods; Julie D Rippeth; Raul Gonzalez; David J Moore; Thomas D Marcotte; Igor Grant; Robert K Heaton
Journal:  Clin Neuropsychol       Date:  2004-05       Impact factor: 3.535

5.  Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale.

Authors:  Clifford A Smith; Wilfred G van Gorp; Elizabeth R Ryan; Stephen J Ferrando; Judith Rabkin
Journal:  J Acquir Immune Defic Syndr       Date:  2003-05-01       Impact factor: 3.731

6.  Validity of two scales in identifying HIV-associated dementia.

Authors:  J P Berghuis; K K Uldall; B Lalonde
Journal:  J Acquir Immune Defic Syndr       Date:  1999-06-01       Impact factor: 3.731

Review 7.  HIV dementia: an evolving disease.

Authors:  Justin C McArthur
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

8.  Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment.

Authors:  David J Moore; Eliezer Masliah; Julie D Rippeth; Raul Gonzalez; Catherine L Carey; Mariana Cherner; Ronald J Ellis; Cristian L Achim; Thomas D Marcotte; Robert K Heaton; Igor Grant
Journal:  AIDS       Date:  2006-04-04       Impact factor: 4.177

9.  Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV.

Authors:  Steven Paul Woods; Julie D Rippeth; Alan B Frol; Joel K Levy; Elizabeth Ryan; Vicki M Soukup; Charles H Hinkin; Deborah Lazzaretto; Mariana Cherner; Thomas D Marcotte; Benjamin B Gelman; Susan Morgello; Elyse J Singer; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-09       Impact factor: 2.475

10.  HIV Dementia Scale: a rapid screening test.

Authors:  C Power; O A Selnes; J A Grim; J C McArthur
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-03-01
View more
  29 in total

1.  Screening for Neurocognitive Impairment in HIV Individuals: The Utility of the Montreal Cognitive Assessment Test.

Authors:  Rodrigo Hasbun; Jairo Eraso; Sweeya Ramireddy; D' Arcy Wainwright; Lucrecia Salazar; Richard Grimes; Michele York; Adriana Strutt
Journal:  J AIDS Clin Res       Date:  2012-12

2.  Education effects on the International HIV Dementia Scale.

Authors:  Drenna Waldrop-Valverde; Ritu Nehra; Sunil Sharma; Ashima Malik; Deborah Jones; Adarsh M Kumar; Raymond L Ownby; Ajay Wanchu; Steve Weiss; Sudesh Prabhakar; Mahendra Kumar
Journal:  J Neurovirol       Date:  2010-07       Impact factor: 2.643

Review 3.  Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use.

Authors:  Jody Kamminga; Luxshimi Lal; Edwina J Wright; Mark Bloch; Bruce J Brew; Lucette A Cysique
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

Review 4.  Screening for cognitive impairment in human immunodeficiency virus.

Authors:  Victor Valcour; Robert Paul; Stephanie Chiao; Lauren A Wendelken; Bruce Miller
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

5.  Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools.

Authors:  Victor G Valcour
Journal:  Top Antivir Med       Date:  2011-12

Review 6.  Update on HIV dementia and HIV-associated neurocognitive disorders.

Authors:  Bruce J Brew; Phillip Chan
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

7.  Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.

Authors:  Kathy Lawler; Mosepele Mosepele; Sarah Ratcliffe; Esther Seloilwe; Katherine Steele; Rudo Nthobatsang; Andrew Steenhoff
Journal:  J Int AIDS Soc       Date:  2010-04-20       Impact factor: 5.396

8.  Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND.

Authors:  Thep Chalermchai; Victor Valcour; Pasiri Sithinamsuwan; Suteeraporn Pinyakorn; David Clifford; Robert H Paul; Somporn Tipsuk; James L K Fletcher; Victor Degruttola; Silvia Ratto-Kim; Nicholas Hutchings; Cecilia Shikuma; Jintanat Ananworanich
Journal:  J Neurovirol       Date:  2013-03-13       Impact factor: 2.643

Review 9.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 10.  Cognitive neuropsychology of HIV-associated neurocognitive disorders.

Authors:  Steven Paul Woods; David J Moore; Erica Weber; Igor Grant
Journal:  Neuropsychol Rev       Date:  2009-05-22       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.